Back to Search
Start Over
The Use of Transdermal Buprenorphine to Relieve Radiotherapy-Related Pain in Head and Neck Cancer Patients.
- Source :
-
Cancer Investigation . Jul2013, Vol. 31 Issue 6, p412-420. 9p. 3 Charts, 7 Graphs. - Publication Year :
- 2013
-
Abstract
- Many head and neck cancer (HNC) patients experience painful therapy-related mucositis and dermatitis. This prospective observational study evaluated transdermal buprenorphine use in HNC patients to relieve treatment-related pain. During treatment with paracetamol or tramadol, visual analogue scale (VAS)-pain scores >30/100 occurred in 26/45 patients 4 weeks after starting cancer therapy, persisting for ≥2 weeks after treatment. These patients subsequently received transdermal buprenorphine. Pain therapy should be more accurately up-titrated to the maximum recommended dose (140 μg/hr) where necessary to maintain pain scores ≤30/100 and, for some patients, should be continued for 6 weeks after the last cancer treatment day. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 07357907
- Volume :
- 31
- Issue :
- 6
- Database :
- Academic Search Index
- Journal :
- Cancer Investigation
- Publication Type :
- Academic Journal
- Accession number :
- 88393003
- Full Text :
- https://doi.org/10.3109/07357907.2013.800094